ANI Pharmaceuticals Inc. (NASDAQ:ANIP) has been assigned an average rating of “Buy” from the eight brokerages that are currently covering the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $67.00.

A number of equities analysts have weighed in on ANIP shares. Citigroup Inc. upgraded shares of ANI Pharmaceuticals to an “outperform” rating and set a $65.00 price target on the stock in a report on Tuesday, July 19th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 price target on the stock in a report on Wednesday, July 20th. Oppenheimer Holdings Inc. lifted their price target on shares of ANI Pharmaceuticals from $65.00 to $71.00 and gave the company an “outperform” rating in a report on Friday, August 5th. Guggenheim reiterated a “buy” rating and issued a $80.00 price target (up previously from $65.00) on shares of ANI Pharmaceuticals in a report on Friday, August 5th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 26th.

In related news, insider Arthur Przybyl sold 37,455 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $66.97, for a total transaction of $2,508,361.35. Following the transaction, the insider now owns 200,788 shares in the company, valued at approximately $13,446,772.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 31.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Fund Advisors increased its stake in ANI Pharmaceuticals by 8.7% in the third quarter. BlackRock Fund Advisors now owns 718,640 shares of the specialty pharmaceutical company’s stock valued at $47,682,000 after buying an additional 57,809 shares during the period. Healthcare Value Capital LLC increased its stake in ANI Pharmaceuticals by 14.5% in the first quarter. Healthcare Value Capital LLC now owns 395,000 shares of the specialty pharmaceutical company’s stock valued at $13,296,000 after buying an additional 50,000 shares during the period. Vanguard Group Inc. increased its stake in ANI Pharmaceuticals by 4.3% in the second quarter. Vanguard Group Inc. now owns 385,670 shares of the specialty pharmaceutical company’s stock valued at $21,527,000 after buying an additional 15,760 shares during the period. State Street Corp increased its stake in ANI Pharmaceuticals by 62.5% in the second quarter. State Street Corp now owns 291,439 shares of the specialty pharmaceutical company’s stock valued at $16,272,000 after buying an additional 112,076 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its stake in ANI Pharmaceuticals by 1.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 192,339 shares of the specialty pharmaceutical company’s stock valued at $12,762,000 after buying an additional 3,163 shares during the period. 50.49% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals (NASDAQ:ANIP) opened at 59.93 on Thursday. The company has a 50-day moving average price of $63.27 and a 200 day moving average price of $58.95. ANI Pharmaceuticals has a 12-month low of $26.80 and a 12-month high of $70.92. The stock has a market cap of $693.99 million, a price-to-earnings ratio of 87.75 and a beta of 3.22.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported $1.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.01. The company had revenue of $38.53 million for the quarter, compared to analyst estimates of $34.34 million. ANI Pharmaceuticals had a net margin of 7.28% and a return on equity of 21.84%. ANI Pharmaceuticals’s revenue for the quarter was up 92.9% on a year-over-year basis. During the same quarter last year, the business earned $0.80 EPS. On average, equities research analysts predict that ANI Pharmaceuticals will post $4.06 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

5 Day Chart for NASDAQ:ANIP

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.